Skip to main content
. 2016 Oct 18;7(47):77622–77634. doi: 10.18632/oncotarget.12731

Figure 1. Resistance to the proteasome inhibitor bortezomib in bortezomib-resistant HCC cell lines HepG2/RTZ and HuH7/RTZ.

Figure 1

A. Dose-response curve of bortezomib-induced growth inhibition of wild-type HepG2 cells and bortezomib-resistant HepG2/RTZ cells. After treatment with various concentrations of bortezomib for 72 h, cell viability was measured using MTT assays. B. Bortezomib-resistant HCC cells demonstrate diminished accumulation of ubiquitinated proteins. Bortezomib-resistant HCC cells and their parental cells were treated with various concentrations of bortezomib for 72 h. Western blot analysis was performed using a monoclonal antibody against polyubiquitinated proteins.